HEALTH × M&A - MVZ VALUATION
MVZ Valuation
in 90 seconds.
Indicative valuation range for your MVZ practice. Based on internal AME transaction database (2026-Q2) + sector-specific adjustments for PEPP reform, KV-seat value, client concentration risk and physician retention.
Inputs
12%
75
20%
8%
15%
Valuation Range
Conservative
7.5x EBITDA
6.0 M €
Median
9.2x EBITDA
7.3 M €
Optimistic
11.9x EBITDA
9.6 M €
Applied Adjustments
- Growth: 0.03x
- Physician retention: 0.04x
- Concentration risk: 0.05x
- KV-seat value: +0.10x
- PEPP risk exposure: -0.27x
- Net adjustment: -0.05x
Decision-Grade Artifact
MVZ valuation (EBITDA multiple + adjustments)
Healthcare valuation decision basis
Snapshot
Conservative
6.0 M €
7.5x
Median
7.3 M €
9.2x
Optimistic
9.6 M €
11.9x
Net adjustment
-0.05x
Insights
- The sector multiple spans 7.5x to 11.9x EBITDA; the median anchors the working value.
- Adjustments net to -0.05x - doctor binding, KV-seat value, growth and PEPP/cluster risk all move the multiple.
What to watch
- MVZ multiples (KPMG Healthcare M&A 2025 + AME deal DB) are consolidator-cycle-sensitive - revalidate near a transaction.
- KV-seat value, klumpenrisiko and PEPP exposure are regulatory/structural - a single factor can swing the price.
Next steps
- Normalise EBITDA (owner comp, one-offs) before applying the multiple.
- Benchmark against 3-5 comparable MVZ transactions.
- Request MVZ Valuation Mandate
Recommendation: Median
7.3 M €
Indicative range: not a formal appraisal.
Data basis: computeMvzBewertung (tested); specialty multiples KPMG Healthcare M&A Report 2025 + internal AME transaction DB (half-yearly).
AME Stop Gate™
This result is indicative. Before any decision, your initiative passes through our three-stage gate process.
G1: Data Cube→
G2: Activation→
G3: Governance
Dr. Marlies Machens · AME STRATICON
Indicative range. Not a formal appraisal. Mandate discovery call recommended for binding figures.
Data version: 2026-Q2 - Source: AME transaction DB + KPMG Healthcare M&A Report 2025 - Update semi-annually
